Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware was written by Ratain, Mark J.;Greenblatt, David J.. And the article was included in Journal of Clinical Pharmacology in 2022.SDS of cas: 2492423-29-5 The following contents are mentioned in the article:
The COVID-19 pandemic has taught us to expect the unexpected. Administration for 2 oral products for the treatment of mild to moderate COVID-19, Pfizer’s combination product, composed of nirmatrelvir 250 mg and ritonavir 100 mg (N+R), and Merck’s molnupiravir both administered over 5 days. While N + R appears to have greater efficacy than molnupiravir, there has been little discussion regarding the unintended consequences of widespread distribution of a ritonavir-containing product. Likewise, the coformulation of N + R enables maintenance of effective antiviral concentrations of nirmatrelvir over a full 24-h period with twice-daily dosing. Food and Drug Administration requires a sufficient set of drug interaction studies, including careful evaluation of the required washout period after completion of the 5-day course. In the interim, providers who choose to prescribe N + R will need to fully understand the implications of initiating a 5-day course of ritonavir. And patients will need to fully understand the risks of taking any drugs (whether or not prescribed) in this context. However, given that many patients who will be seeking N + R have already declined medical recommendations for vaccination, it is likely that some patients will also choose to ignore the warnings regarding the risks of certain concomitant drugs, which include ivermectin, as well as many recreational drugs. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5SDS of cas: 2492423-29-5).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. THF (Tetrahydrofuran) is a stable compound with relatively low boiling point and excellent solvency. THF (Tetrahydrofuran) is also used as a starting material for the synthesis of poly(tetramethylene ether) glycol (PTMG), etc.SDS of cas: 2492423-29-5
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem